Abstract
End-stage renal disease (ESRD) has become a challenging health problem worldwide. Currently, ESRD patients treated with hemodialysis mainly undergo low-flux hemodialysis, high-flux hemodialysis (HF-HD), or hemodiafiltration (HDF). The clearance of middle and large molecules is, however, quite insufficient as regards HF-HD, HDF, and on-line HDF. An unsatisfactory prognosis has led to improved dialysis technology and materials; both protein-leaking membranes and high cut-off membranes increase the clearance of uremic toxin, but in clinical application they may induce albumin loss. Novel membranes with similar clearance efficiency but little impact on albumin leakage are yet to be developed. To enhance the removal of uremic toxins and increase membrane permeability, a high retention onset (HRO) membrane with larger pore size and HRO, once defined as medium cut-off, has been developed in the past few years. Such a membrane enables leakage of larger size molecules including albumin. The dialysis using HRO membranes has recently been proposed as expanded hemodialysis (HDx). Theoretically, HDx could promote the removal of more toxin solutes retained in the blood of ESRD patients, and improve the outcomes of dialysis. However, randomized controlled trials are required to evaluate the long-term efficacy, safety, and side effects of HDx in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
